Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Asset Writedowns and Impairment (2023 - 2024)

Pediatrix Medical (MD) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$3.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment fell 102.14% to -$3.6 million in Q4 2024 year-over-year; TTM through Dec 2025 was -$3.6 million, a 102.19% decrease, with the full-year FY2024 number at $178.4 million, up 6.01% from a year prior.
  • Asset Writedowns and Impairment was -$3.6 million for Q4 2024 at Pediatrix Medical, down from $168.3 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $168.3 million in Q4 2023 to a low of -$3.6 million in Q4 2024.